CONTENTS

1. INTRODUCTION
2. YEAR 2008
3. YEAR 2009
4. YEAR 2010
5. YEAR 2011
6. YEAR 2012 (TILL FIRST QUARTER)
7. CONCLUSION

Introduction
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our
customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have
approximately 39,000 employees and serve customers within pharmaceutical and biotech companies,
hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well
as in environmental and process control industries. We create value for our key stakeholders through
three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique
combination of innovative technologies, convenient purchasing options and a single solution for
laboratory operations management. Our products and services help our customers solve complex
analytical challenges, improve patient diagnostics and increase laboratory productivity.
BRANDS
Acros Organics
Fine chemicals in pre-pack and semi-bulk quantities, offering more than 18,000 chemicals to research
and industrial customers.
Capitol Vial
Specializes in manufacturing a variety of containers including milk vials for dairy testing, specimen
collection and transport containers for drugs-of-abuse testing, environmental-sampling containers and
quality control sample storage containers.
Chromacol
Developer of a range of vials, caps and seals to the chromatography consumables market.
EP Scientific Products
Critical-environment glass and plastic disposable products used by the pharmaceutical and
semiconductor industries as well as standard and custom glass containers and chemical preservatives
used by the environmental-testing industry.
Fisher BioReagents
Superior quality and value-added laboratory reagents qualified for molecular biology, cell biology and
protein chemistry.

Fisher Chemical
An extensive portfolio of analytical reagents for use in a broad range of scientific-testing applications in
the global marketplace.
I-CHEM
Comprehensive range of sample collection products.
La Pha Pack
A complete range of consumables for GC, HPLC and Headspace analysis
Maybridge
Highly innovative drug-like molecules and screening compounds for drug discovery and development.
Metavac
Manufacturer and developer of thin-film coatings, optical and electro-optical products for commercial,
industrial, military, medical and life-science applications.
Molecular BioProducts
Plastic-injection molding company specializing in the manufacturing of pipet tips for automated liquid
handling and manual liquid handling used in life science research laboratories where sample transfers
are conducted.
Nalgene
Designer, developer, and manufacturer of plastic products for use in labware, packaging, environmental,
biotech and life science applications.
Nalgene Outdoor
Consumer-market distributor of Nalgene products such as bottles, containers, jars, flasks, travel
accessories and more.
Nunc
Value-added plastic products to be used primarily in R&D laboratories by biotech and pharmaceutical
companies, universities, hospital labs and industrial customers for diagnostic-kit and vaccine production.

Year 2008
OVERVIEW
In the year 2008, Thermo Fisher strengthened their position as the world leader in serving science by
achieving their goals for 2008. Thermo Fisher Scientific reached an incredible milestone at the end of the
year, with an 8 percent increase in annual revenues that put them over the $10 billion mark, to a record
$10.5 billion.
REASONS FOR GROWTH
1. They continued to invest in building their industry-leading portfolio, which includes an attractive
mix of technologies, products and services.
2. Two-thirds of their revenue comes from recurring sales of consumables and services, while only
one-third is derived from capital items, such as instruments and equipment. In a tough
economy, customers typically continue to buy necessary consumables and services, while they
might delay higher-priced capital purchases.
3. The companys primary end markets are life sciences and healthcare, which tend to be less
sensitive to economic cycles.

FINANCIAL HIGHLIGHTS
REVENUE

REVENUE
12000
10000
8000
6000
4000
2000
0
US $ (millions)

2008
10498

2007
9746.4

2006
3791.6

2005
2633

Year 2009
OVERVIEW
In 2009, the economic crisis was hitting customers of Thermo Fisher with full force. Not only did this
affect their capital-budget purchases of instrumentation and equipment, but it caused them to reduce
inventory levels of basic laboratory supplies as well, which affected sales of Thermo Fisher consumables
products in the first quarter. This led to a full year revenue decline of 4 percent to $10.1 billion
compared with 2008. However, the company saw sequential improvement in revenue performance
every quarter as the year progressed, and ended with revenue growth of 7 percent in the fourth
quarter.
FINANCIAL HIGHLIGHTS
REVENUE

REVENUE
12000
10000
8000
6000
4000
2000
0
US $ (millions)

2009
10109.7

2008
10498

2007
9746.4

2006
3791.6

Year 2010
OVERVIEW
2010, was an excellent year for Thermo Fisher. They achieved and exceeded all their goals for 2010 with
a top-line revenue growth of 7 percent, to $10.79 billion for the full year.
Thermo Fisher credits the following strategy for their top-line revenue growth.
Commitment to technology innovation
Expanding their presence in emerging markets around the world
Thermo increased their total R&D investment in 2010 by more than $40 million, for a total of
approximately $285 million, to strengthen their leadership position in innovation. The companys
previous investments led to a number of exciting new products in 2010 as represented by their Thermo
Scientific brand, filling their pipeline across their instruments, software, equipment and consumables
offerings.
FINANCIAL HIGHLIGHTS
REVENUE

REVENUE
12000
10000
8000
6000
4000
2000
0

2010
2009
US $ (millions) 10788.7 10109.7

2008
10498

2007
5420

REVENUE BY END MARKET

REVENUE BY GEOGRAPHY

REVENUE BY PRODUCT CATEGORY

Year 2011
OVERVIEW
The year 2011, was an excellent year for the company as revenues rose 11 percent to $11.73 billion.
According CEO, Marc N. Casper, three distinct characteristics give Thermo Fisher a clear market
advantage:
Commitment to innovation
Large and growing footprint in emerging markets
Customer value proposition that is second to none
IMPORTANT MILESTONES

In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand in testing for allergies
and autoimmune diseases for Euro2.47 billion ($3.5 billion) in cash purchase
Thermo Fisher spent approximately $340 million on R&D in 2011
In 2011, Thermo Fisher launched the Q Exactive system, their latest innovation in hybrid mass
spectrometry.
Established the Specialty Diagnostics Segment to highlight growing portfolio of high-value
diagnostic products for improving patient care
Revenue from emerging markets China and India, each grew by more than 20 percent in 2011.
Acquired Dionex in 2011 which gave the company leadership in air-quality monitoring and the
water-analysis products
FINANCIAL HIGHLIGHTS
REVENUE

REVENUE
12000
11500
11000
10500
10000
9500
9000

2011
2010
US $ (millions) 11725.9 10570.2

2009
9911.6

2008
10313.2

Year 2012(Till First Quarter)

OVERVIEW
The first quarter of 2012, gave an excellent start for the company as their teams executed well, their
growth drivers continued to gain traction, and the cost-reduction programs we put in place delivered
according to their plans. They delivered strong revenue growth of $3.1 billion, with a 14% increase in
the quarter.
Turning to industrial and applied markets, they saw continued strength across their portfolio, with solid
performance in thier businesses serving these end markets. A couple examples were strong sales of
their molecular spectroscopy instruments for quality control laboratories, as well as robust demand for
our process instruments for mining and minerals customers. Last, in pharmaceutical and biotech, they
continue to grow rapidly and gain share with these customers. They had another excellent quarter in
bio-process production business, with strong sales of Sera, media, and single-use disposable production
systems. Their BioPharma services business, where we are the largest outsourcing partner for clinical
trials logistics, continues to grow in the double digits
Coming to the new product launches, At Pittcon, they debuted their new ion chromatography platform,
the ICS 4000, which is the world's first integrated capillary high-pressure IC system. It's ideal for highvolume environmental and industrial laboratories that demand rapid analysis without compromising
performance.

FINANCIAL HIGHLIGHTS
REVENUE

REVENUE
3200
3100
3000
2900
2800
2700
2600
2500
US $ (millions)

2012Q1
3100.3

2011Q1
2721.4

CONCLUSION
Thermo Fisher Scientific carried their momentum of strong financial performance into 2012
by delivering 27 percent growth in adjusted EPS on solid top-line results. Their revenue
growth was fueled largely by demand for analytical instruments across a broad base of
customers, as well as ongoing strength in our biopharma services business. In addition, our
investments in emerging markets are also continuing to payoff which is highlighted by
China.